INTRODUCTION
============

A single mammalian cell can exert tensile forces on its surroundings, which can regulate cell shape, motility, and in the case of stem cells, differentiation ([@B34]; [@B8]; [@B4]). At the multicellular level, such forces contribute significantly to collective cell migration, tissue morphogenesis during development, and wound healing ([@B49]; [@B50]; [@B12]). Actomyosin stress fibers (SFs) are partly responsible for generating and transmitting these forces to the extracellular matrix (ECM) through direct attachment to focal adhesions as well as through interactions with other cytoskeletal structures ([@B5]; [@B21]; [@B20]; [@B43]; [@B26]). SFs are composed of F-actin, cross-linking proteins such as α-actinin, and in some cases, the force-generating motor protein nonmuscle myosin II (NMMII).

NMMII is composed of two essential light chains (ELCs), two regulatory light chains (RLCs), and two heavy chains ([@B56]; [@B1]). Each heavy chain contains a globular head domain, which can bind to F-actin and hydrolyze ATP. This ATP hydrolysis is needed to power the contractile sliding of myosin filaments against actin filaments, leading to a build-up of tension within the SF ([@B41]). Myosin motor activity and filament formation are strongly regulated by phosphorylation of RLC at Ser19 and Thr18, which allows NMMII to assemble into linear thick filaments ([@B56]). Monophosphorylation (p-RLC) at Ser19 alters the conformation of the NMMII head domains to permit ATPase activity ([@B60]) and diphosphorylation (pp-RLC) of Thr18 and Ser19 further enhances ATPase activity ([@B54]; [@B18]; [@B32]). Each RLC phosphospecies appears to play different roles in governing SF assembly and tension generation, even though both can coexist within a single SF ([@B1]). For example, while p-RLC has been reported to contribute to SF assembly and to distribute along the entire SF length, pp-RLC preferentially localizes to the most contractile regions of the SF interior as observed during time-lapse imaging ([@B59]). While these and other observations hint that p-RLC and pp-RLC contribute differently to SF tensile functions, a causal relationship has not been established.

RLC phosphorylation is driven by two orthogonal kinases: the Ca^2+^/calmodulin-dependent myosin light chain kinase (MLCK) and the RhoA effector Rho-associated kinase (ROCK). MLCK is encoded by one gene and exists in two forms: long MLCK (∼211 kDa) and short MLCK (∼150 kDa) which lacks the N-terminal extension thought to be associated with actin ([@B3]). Both MLCK forms directly phosphorylate RLC. On the other hand, ROCK promotes RLC phosphorylation either by direct phosphorylation of RLC or by phosphorylating and inactivating RLC phosphatase. Precisely how these kinases differentially contribute to RLC phosphorylation remains unclear, with the few studies focused on this question producing differing results depending on the cellular system and method of perturbation. For example, pharmacologic ROCK inhibition has been reported to reduce pp-RLC but not p-RLC levels in epithelial cells and thrombin-activated porcine aortic endothelial cells, whereas pharmacologic MLCK inhibition (via ML-9 or Ca^2+^ depletion) has been observed to affect neither phosphorylation state significantly ([@B59]; [@B13]). In contrast, RLC monophosphorylation in human platelets is Ca^2+^ dependent, implying activation by MLCK ([@B11]). In reconstituted systems, however, MLCK has been reported to produce both p-RLC and pp-RLC ([@B15]; [@B16]; [@B54]). Complicating matters further, there are two mammalian isoforms of ROCK (ROCK1 and ROCK2), and recent isoform-specific knockdown studies have shown that ROCK1 induces pp-RLC and regulates actin microfilament bundle formation in fibroblasts, whereas ROCK2 preferentially regulates RLC monophosphorylation, adhesion maturation and cortical contractility ([@B63] [@B62]; [@B33]).

In addition to differences in phosphorylation state, MLCK and ROCK appear to act upon different subcellular pools of SFs, with MLCK preferentially contributing to the assembly of SFs at the periphery of the cell and ROCK preferentially contributing to the assembly of SFs at the cell center ([@B52]; [@B22]; [@B51]). Subcellular laser ablation (SLA) measurements reveal corresponding differences in the SF viscoelastic properties of these peripheral and central SFs, with peripheral SFs releasing more elastic energy than central SFs when photo-severed ([@B51]). The spatial distribution of p-RLC and pp-RLC appears to be much more nuanced, as both species are observed within both peripheral and central SFs. Perhaps for this reason, it has remained unclear how p-RLC and pp-RLC differentially contribute to the mechanical functions of each SF subpopulation ([@B39]; [@B38]; [@B57]). Overall, these observations raise the question of whether ROCK and MLCK preferentially control central and peripheral SF formation and mechanical properties by preferential phosphorylation of RLC.

In this study, we investigate mechanistic connections between MLCK and ROCK activity, RLC phosphorylation states, and SF viscoelastic properties using a combination of cell biological and single-cell biophysical approaches. We find that both ROCK1 and ROCK2 regulate central SF retraction kinetics via increased diphosphorylation of RLC, whereas MLCK regulates peripheral SF retraction kinetics via increased monophosphorylation of RLC. An important innovation in our approach is the use of inducibly graded expression of ROCK and MLCK, which enables us to construct quantitative relationships between RLC phosphorylation and SF viscoelastic properties.

RESULTS
=======

To investigate functional contributions of MLCK and ROCK to RLC phosphorylation and SF function, we stably overexpressed constitutively active (CA) mutants of ROCK and MLCK under a doxycycline-inducible promoter in two cell lines: U2OS human osteosarcoma and U373MG human glioblastoma cells ([Figure 1A](#F1){ref-type="fig"}; [@B29]; [@B61]). The mutants p160ROCK Δ3 (human CA-ROCK1) and ROCK CAT (bovine CA-ROCK2) lack the RhoA binding domain, thereby unleashing kinase activity in the absence of RhoA-GTP binding, whereas rabbit smooth muscle short MLCK ED785-786KK (CA-MLCK) lacks a functional autoinhibition domain ([@B10]; [@B27]; [@B17]). Importantly, doxycycline induction allows titration of gene expression over a continuous range, which in turn enables elucidation of quantitative relationships between expression and mechanobiological phenotype in a manner not possible with pharmacological inhibition or transient plasmid overexpression ([@B28] [@B30]; [@B29]; [@B14]). Understanding this dose-response relationship is an important experimental design consideration given that the relationship between myosin activation and mechanobiological phenotype is often highly nonlinear ([@B29]; [@B36]).

![Graded control over the expression of a constitutively active form of MLCK (CA-MLCK) and ROCK2 (CA-ROCK2). (A) Schematic of doxycycline-inducible lentiviral system, where X encodes MLCK, ROCK1, or ROCK2. (B) Representative Western blot showing expression levels of endogenous MLCK, CA-MLCK, and GAPDH in U2OS (left) and U373MG cells (right) as a function of doxycycline concentration. U2OS cells were probed with rabbit ant-MLCK (Abcam 76092) and U373MG cells were probed with mouse anti-MLCK (Sigma M7905). Expression levels of CA-MLCK were quantified, normalized to GAPDH and to the highest doxycycline concentration for each cell line, and plotted below the respective Western blots (*n* = 4 blots for U2OS and *n* = 6 blots for U373MG). (C) Representative Western blot showing expression levels of endogenous ROCK2, CA-ROCK2, and GAPDH in U2OS (left) and U373MG (right) cells in the presence of various amounts of doxycycline. Expression levels of CA-ROCK2 were quantified, normalized to GAPDH and to the highest doxycycline concentration, and plotted below the respective Western blots (*n* = 10 blots for U2OS and *n* = 10 blots for U373MG at the maximum doxycycline concentration). Statistical parameters shown represent the Spearman's rank correlation coefficient (ρ) and *p* value.](3832fig1){#F1}

We first confirmed that we can indeed express each kinase in a gradient by quantifying CA-MLCK ([Figure 1B](#F1){ref-type="fig"}) and CA-ROCK2 ([Figure 1C](#F1){ref-type="fig"}) levels as a function of doxycycline concentration for both cell lines. As expected, CA-MLCK and CA-ROCK2 were undetectable in the absence of doxycycline for both cell lines. The expression of each kinase increased in a statistically significant manner with increasing doxycycline concentration (quantification shown in [Figure 1, B and C](#F1){ref-type="fig"}; Spearman correlation coefficients ρ~U2OS,\ CA-MLCK~ = 0.87, ρ~U373,\ CA-MLCK~ = 0.94, ρ~U2OS,\ CA-ROCK2~ = 0.82, ρ~U373,\ CA-ROCK2~ = 0.83). We also successfully produced similarly graded expression of CA-ROCK1 as shown by increasing intensity of the Myc tag with doxycycline (Supplemental Figure S1). Moreover, we compared the expression of the CA constructs relative to the levels of the endogenous kinases. We observed that the expression levels of CA-ROCK2 relative to endogenous were 0.85-fold for U2OS and 1.66-fold at the highest doxycycline concentration for U373MG cells, respectively (Supplemental Figure S2). The expression levels of CA-MLCK relative to endogenous MLCK were higher for both cell lines ranging around 1-fold for U2OS and 4.8-fold for U373MG cells at the highest doxycycline concentrations (Supplemental Figure S2; U2OS CA-MLCK was normalized to 130 kDa MLCK, whereas U373MG CA-MLCK was normalized to 211 kDa MLCK). Overall, we observe that our system allows us to produce graded but modest overexpression of ROCK2 and MLCK in both cell lines over a range that enables us to study the relationship between kinase expression and mechanobiological phenotypes.

As described earlier, our and others' pharmacological studies have demonstrated that ROCK and MLCK regulate the formation of different subsets of SFs, with ROCK inhibition disrupting central SFs and MLCK inhibition disrupting peripheral SFs ([@B22]; [@B51]). We therefore hypothesized that graded increases in the expression of each kinase would produce graded changes in each corresponding SF subpopulation, which may in turn drive alterations in cell morphology. The two cell lines chosen exhibit different central SF architectures: U2OS cells feature prominent ventral SFs ([Figure 2, A and C](#F2){ref-type="fig"}, at 0 ng/ml doxycycline), which localize to the cell rear and terminate in FAs, whereas U373MG cells exhibit more transverse arcs, which lie parallel to the leading edge and anchor internally within the SF network ([Figure 2, B and D](#F2){ref-type="fig"}, at 0 ng/ml doxycycline). With increasing doxycycline concentration, both U2OS CA-MLCK and U373MG CA-MLCK cells exhibited brighter and slightly thicker peripheral SFs ([Figure 2, A](#F2){ref-type="fig"} and B; highlighted insets and arrowheads point to peripheral SFs). Additionally, expression of CA-MLCK in U373MG cells resulted in the formation of smaller actin fibers close to the peripheral SFs ([Figure 2B](#F2){ref-type="fig"}; 200 ng/ml inset). In contrast, CA-ROCK2 expression increased the density of central SFs for both cell lines ([Figure 2, C and D](#F2){ref-type="fig"}). Specifically, U2OS CA-ROCK2 cells exhibited thicker central SFs with increasing doxycycline concentrations compared with the 0 ng/ml doxycycline condition ([Figure 2C](#F2){ref-type="fig"}; highlighted insets and arrowheads pointing to central ventral SFs). At higher concentrations, central SFs sometimes formed mesh-like structures with indistinguishable SFs. Similarly, expression of CA-ROCK2 in U373MG cells led to the formation of ventral SFs within the cell center as compared with cells cultured in the 0 ng/ml doxycycline condition, which exhibited a more poorly defined SF network ([Figure 2D](#F2){ref-type="fig"}; highlighted inset, and arrowheads point to central ventral SFs). At higher doxycycline concentrations, U373MG CA-ROCK2 cells also exhibited brighter and thicker central SFs ([Figure 2D](#F2){ref-type="fig"}; 120 ng/ml doxycycline inset). We also saw similar effects on central SF architecture with expression of CA-ROCK1 (Supplemental Figure S3). Thus, both cell lines exhibit similar ROCK-dependent enhancement of central SFs and MLCK-dependent enhancement of peripheral SFs.

![Graded expression of CA-MLCK alters peripheral SF architecture, whereas CA-ROCK2 expression alters central SF architecture. F-actin images of (A) U2OS CA-MLCK and (B) U373MG CA-MLCK cultured in various doxycycline concentrations. Arrowheads point to peripheral SFs and insets highlight peripheral SFs of interest. F-actin images of (C) U2OS CA-ROCK2 and (D) U373MG CA-ROCK2 cultured in various doxycycline concentrations. Arrowheads point to central SFs and insets highlight central SFs of interest. Fluorescence intensity was normalized to the 0 ng/ml doxycycline concentration for all panels with the exception of B where the 0 ng/ml doxycycline condition is set at a higher intensity than the others. Scale bars = 10 µm; inset scale bars = 2 µm.](3832fig2){#F2}

To determine whether the CA constructs exhibit preferential localization, we performed immunostaining in both U2OS and U373MG CA-MLCK and CA-ROCK2 cells cultured in the presence and absence of doxycycline. Previous work has shown that MLCK has an actin-binding domain in its N-terminus ([@B42]). Consequently, long MLCK preferentially localizes to SFs, whereas short MLCK exhibits a more cytoplasmic localization ([@B3]). In both U2OS and U373MG cells, endogenous MLCK exhibits diffuse localization (Supplemental Figure S4). The addition of doxycycline increases the fluorescence intensity due to expression of short CA-MLCK but does not change the localization patterns. Endogenous ROCK2 and CA-ROCK2 also exhibit diffuse localization for both U2OS and U373MG cell lines. Similar localization patterns were also observed with overexpression of CA-ROCK1 in U2OS cells. Overall, the kinases do not seem to differ in their localization despite the distinct changes in SF architecture observed with expression of each kinase.

To quantify how changes in the expression of each kinase translate into RLC mono- and diphosphorylation levels, we performed Western blots using phospho-specific antibodies. First, we explored whether any changes in RLC phosphorylation were observed in the presence and absence of doxycycline induction of MLCK and ROCK (Supplemental Figure S5). Induction of CA-MLCK produced a statistically significant increase in p-RLC but not in pp-RLC for both cell lines (p~U2OS,\ p-RLC\ (rabbit)~ = 0.035, p~U2OS,\ pp-RLC\ (rabbit)~ = 0.75, p~U373,\ p-RLC\ (mouse)~ = 0.0092, p~U373,\ pp-RLC\ (rabbit)~ = 0.061; Kruskal--Wallis followed by Dunn's nonparametric test for U2OS and Student's *t* test for U373MG). In contrast, induction of CA-ROCK2 increased pp-RLC but not p-RLC in both cell lines (p~U2OS,\ p-RLC\ (rabbit)~ = 0.10, p~U2OS,\ pp-RLC\ (rabbit)~ = 0.0006, p~U373,\ p-RLC\ (mouse)~ = 0.072, p~U373,\ pp-RLC\ (rabbit)~ = 0.019; Student's *t* test of U373MG and analysis of variance followed by Student's *t* test for U2OS). We next asked how graded variations in the activity of each kinase altered phosphorylation states ([Figure 3](#F3){ref-type="fig"}). In both cell lines, graded induction of CA-MLCK expression produced a monotonic increase in p-RLC ([Figure 3A](#F3){ref-type="fig"}, empty gray circles; Spearman correlation coefficients ρ~U2OS,\ p-RLC\ (mouse)~ = 0.65, ρ~U373,\ p-RLC\ (mouse)~ = 0.55). Interestingly, CA-MLCK in both U2OS and U373MG cells slightly increased pp-RLC in a graded manner as well, consistent with a sequential phosphorylation mechanism ([Figure 3A](#F3){ref-type="fig"}, solid triangles; Spearman correlation coefficients ρ~U2OS,\ pp-RLC\ (rabbit)~ = 0.30, ρ~U373,\ pp-RLC\ (rabbit)~ = 0.50). In both cell lines, increasing the expression of CA-ROCK2 increased pp-RLC ([Figure 3B](#F3){ref-type="fig"}, solid triangles circles; Spearman correlation coefficients ρ~U373,\ pp-RLC\ (rabbit)~ = 0.38, ρ~U2OS,\ pp-RLC\ (rabbit)~ = 0.61), while no graded change was observed in p-RLC in both U2OS and U373MG cells ([Figure 3B](#F3){ref-type="fig"}, empty gray circles; Spearman correlation coefficients ρ~U2OS,\ p-RLC\ (mouse)~ = −0.17, ρ~U373,\ p-RLC~ = −0.28). We also observed the same trends with CA-ROCK1 expression in U2OS cells (Supplemental [Figure S5](#F5){ref-type="fig"}), suggesting that both ROCK1 and ROCK2 isoforms preferentially produce pp-RLC.

![Graded increases in CA-MLCK and CA-ROCK2 produce graded changes in p-RLC and pp-RLC. (A) Representative Western blots probed for p-RLC and pp-RLC in U2OS CA-MLCK (top) and U373MG CA-MLCK (bottom). Phosphorylation levels were quantified, normalized to GAPDH and CA-MLCK + 0 ng/ml doxycycline for each cell line, and plotted below the respective Western blots. p-RLC is shown by empty gray circles, whereas pp-RLC is shown by black triangles (U2OS: *n* = 6 blots for p-RLC \[mouse\] and 7 blots for pp-RLC \[rabbit\] blots; U373MG: *n* = 8 blots for p-RLC \[mouse\] and *n* = 9 blots for pp-RLC \[rabbit\]). (B) Representative Western blots probed for pp-RLC and p-MCL in U2OS CA-ROCK2 (top) and U373MG CA-ROCK2 (bottom). Phosphorylation levels were quantified, normalized to GAPDH and CA-ROCK2 + 0 ng/ml doxycycline for each cell line, and plotted below the respective Western blots. p-RLC is shown as empty, black circles, whereas pp-RLC is shown as solid, black triangles (U2OS: *n* = 4 blots for p-RLC \[mouse\] and *n* = 11 blots for pp-RLC \[rabbit\] expression; U373MG: *n* = 9 blots for pp-RLC \[rabbit\] and *n* = 6 blots for p-RLC \[mouse\]). Statistical parameters shown represent the Spearman's rank correlation coefficient (ρ) and *p* value.](3832fig3){#F3}

Given the strong influence of ROCK1/2 on central SFs and pp-RLC levels, and that of MLCK on peripheral SFs and p-RLC levels, we wondered whether the observed kinase-dependent RLC phospho-species localized to the respective kinase-dependent SF subpopulations. RLC-phospho-specific immunostaining of CA-MLCK ([Figure 4A](#F4){ref-type="fig"}) and CA-ROCK2 cells ([Figure 4B](#F4){ref-type="fig"}) indeed revealed an MLCK-dependent increase in p-RLC in the cell periphery ([Figure 4A](#F4){ref-type="fig"}, highlighted inset) and a ROCK-dependent increase in pp-RLC in the cell center ([Figure 4B](#F4){ref-type="fig"}, highlighted inset). Quantification of this localization revealed a statistical increase in p-MLC in both peripheral (black) and central SFs (gray) for both U2OS and U373MG CA-MLCK cells ([Figure 4C](#F4){ref-type="fig"}, top row). The details of this relationship varied with cell line. U2OS cells exhibited a much greater enhancement of p-RLC in peripheral SFs than central SFs (U2OS: 2.6-fold for peripheral vs. 1.6-fold for central; U373MG: 2.0-fold for peripheral vs. 1.92-fold for central) as well as a slight increase in the amount of pp-RLC in peripheral SFs (U2OS: 1.3-fold increase; U373MG: 1.1-fold increase; [Figure 4C](#F4){ref-type="fig"}, bottom row). Induction of CA-ROCK2 produced an increase in pp-RLC in central SFs for both cell lines (U2OS: 1.94-fold; U373MG: 1.2-fold; [Figure 4D](#F4){ref-type="fig"}, bottom row). For U2OS cells, a small increase in the amount of p-RLC was also observed in central SFs (U2OS: 1.28-fold increase; [Figure 4D](#F4){ref-type="fig"}, top row). Taken together with our earlier SF morphometric observations ([Figure 2](#F2){ref-type="fig"}) and Western blots ([Figure 3](#F3){ref-type="fig"}), these results indicate that ROCK promotes formation of central SFs and an associated central localization of pp-RLC, whereas MLCK promotes formation of peripheral SFs and an associated peripheral localization of p-RLC.

![CA-MLCK expression regulates RLC phosphorylation in peripheral SFs, whereas CA-ROCK2 expression regulates RLC phosphorylation in central SFs. Representative fluorescence images of (A) U2OS CA-MLCK (left) and U373MG CA-MLCK (right) cells and (B) U2OS CA-ROCK2 and U373MG CA-ROCK2 cells cultured in the presence and absence of doxycycline stained for p-RLC (top row, third and fourth rows in magenta) and pp-RLC (second row, third and fourth rows in green). Scale bars = 10 µm; inset scale bars = 5 µm. Fluorescence intensity of all images is normalized to that of 0 ng/ml doxycycline for each condition. (C) Quantification of immunofluorescence intensity of p-RLC (top row) and pp-RLC (bottom row) within central (gray) and peripheral (black) SFs for U2OS and U373MG CA-MLCK cells cultured in the presence and absence of doxycycline (*n* = 46, 46, 41, 55, 62, 53, 60, and 51 cells collected from three independent experiments for each condition, respectively, from left to right). Intensities were normalized to the average intensity value of either U2OS or U373MG CA-MLCK cells cultured in the absence of doxycycline for each experiment. (D) Quantification of immunofluorescence intensity of p-RLC (top row) and pp-RLC (bottom row) within central (gray) and peripheral (black) SFs for U2OS and U373MG CA-ROCK2 cells cultured in the presence and absence of doxycycline (*n* = 41, 32, 39, 31, 75, 72, 75, and 71 cells collected from three independent experiments analyzed per condition, respectively, from left to right). Intensities were normalized to the average intensity value of either U2OS or U373MG CA-ROCK2 cells cultured in the absence of doxycycline per each experiment (\*\**p* \< 0.01; \*\*\**p* \< 0.001; Mann-Whitney test).](3832fig4){#F4}

To determine whether the localized changes in RLC phosphorylation caused by each kinase produced changes in the mechanical properties of the associated SFs, we performed SLA to sever individual central and peripheral SFs of U2OS CA-ROCK2 and U2OS CA-MLCK cells cultured in the presence and absence of doxycycline. As in our previous studies, we photo-severed single SFs and fitted the time-dependent retraction of the two SF ends to the Kelvin-Voigt model of viscoelasticity. This model is described by two parameters: a viscoelastic time constant (τ), reflecting the SF's effective viscosity to elasticity ratio, and a plateau retraction distance (*L~o~*), reflecting the elastic energy dissipated by half of the severed SF ([Figure 5A](#F5){ref-type="fig"}; [@B23]; [@B6]; [@B20]). Whereas *L*~o~ and τ for peripheral SFs were insensitive to CA-ROCK2 induction ([Figure 5B](#F5){ref-type="fig"}), both parameters statistically increased with CA-MLCK induction ([Figure 5B](#F5){ref-type="fig"}). For central SFs, both *L~o~* and τ were influenced by CA-ROCK2 induction but not by CA-MLCK induction ([Figure 5C](#F5){ref-type="fig"}). Notably, both CA-ROCK1 and CA-ROCK2 influenced SF mechanics in a similar manner (Supplemental [Figure S6](#F6){ref-type="fig"} and [Figure 5, B](#F5){ref-type="fig"} and C). Thus, ROCK and MLCK preferentially regulate the viscoelastic properties of central and peripheral SFs, respectively.

![CA-MLCK and CA-ROCK2 regulate the viscoelastic properties of distinct SF subpopulations. (A) SF retraction analysis. *D~a~*: SF material destroyed by ablation; 2*L*: distance between SF ends over time (*L* is the retraction distance of a severed SF fragment); *t*: time. *L*-*t* curves for each stress fiber are fitted to a Kelvin-Voigt model to determine *L~o~*~,~ whose magnitude correlates with the SF's dissipated elastic energy, and τ, the viscoelastic time constant, which reflects the ratio of viscosity to elasticity. (B) *L~o~* and τ values of peripheral SF ablation for U2OS CA-ROCK2 and CA-MLCK cells cultured in the presence and absence of doxycycline (*n* = 21, 32 for U2OS CA-ROCK2, *n* = 42, 47 for U2OS CA-MLCK). (C) *L~o~* and τ values of central SF ablation for U2OS CA-ROCK2 and CA-MLCK cells cultured in the presence and absence of doxycycline (*n* = 49, 51 for U2OS CA-ROCK 2, *n* = 22, 19 for U2OS CA-MLCK). Boxes represent 25th and 75th percentiles; whiskers represent 10th and 90th percentiles. Cross represents the mean of the distribution. Statistical differences calculated using Mann-Whitney (\**p* \< 0.005, \*\**p* \< 0.0005). Scale bars = 10 µm.](3832fig5){#F5}

![SF mechanical properties increase in a graded manner following graded expression of RLC phosphorylation. (A) *L~o~* and τ values of peripheral (left, dark gray) and central (right, orange) SF ablation of CA-MLCK cells cultured in various concentrations of doxycycline (*n* = 42, 24, 39, 37, 25, and 47 cells for peripheral SF ablation of CA-MLCK, *n* = 22, 14, 7, 14, 9, and 19 cells for central SF ablation). (B) *L~o~* and τ values of peripheral (left, dark gray) and central (right, orange) SF ablation of CA-ROCK2 cells cultured in various concentrations of doxycycline (*n* = 21, 15, 6, 16, 6, 14, and 21 cells for peripheral SF ablation; *n* = 49, 41, 31, 25, 40, and 38 cells for central SF ablation). A, B, and C statistical families show statistical differences (*p* \< 0.05) determined using Dunn's test for multiple comparisons of nonnormally distributed data. Boxes represent 25th and 75th percentiles; whiskers represent 10th and 90th percentiles. Cross represents the distribution mean. (C) Viscoelastic retraction parameters *L~o~* and τ of peripheral (black) and central SFs (orange) of U2OS CA-MLCK cells plotted vs. the observed increase in p-RLC (replotted from [Figure 3A](#F3){ref-type="fig"}). (D) Viscoelastic retraction parameters *L~o~* and τ of peripheral (black circles) and central SFs (solid orange circles) and peripheral (black circles) of U2OS CA-ROCK2 cells plotted vs. the observed increase in pp-RLC (replotted from [Figure 3B](#F3){ref-type="fig"}). Orange values correspond to central SF ablation Spearman's rank correlation coefficient analysis, whereas black values correspond to Spearman's rank correlation coefficient analysis for peripheral SF ablation. Error bars of *x*-axis values were determined based on Western blot quantifications shown in [Figure 3](#F3){ref-type="fig"}. All error bars represent SEM.](3832fig6){#F6}

As noted earlier, an important advantage of graded, inducible expression systems is the ability to construct quantitative relationships between effector level and phenotype. Given our ability to associate RLC phosphorylation levels at a specific doxycycline concentration ([Figure 3](#F3){ref-type="fig"}) and our ability to elucidate SF viscoelastic properties at these same doxycycline concentrations, we were uniquely well positioned to explore correlations between phospho-RLC levels and SF mechanics. To answer this question, we performed SLA on U2OS cells expressing either CA-MLCK ([Figure 6A](#F6){ref-type="fig"}) or CA-ROCK2 ([Figure 6B](#F6){ref-type="fig"}) cultured in various doxycycline concentrations. We observed statistical differences in the dissipated elastic energy (*L~o~*) and viscoelastic time constant (τ) for peripheral SFs of CA-MLCK ([Figure 6A](#F6){ref-type="fig"}, gray) and in both *L~o~* and τ for central SFs of CA-ROCK2 cells ([Figure 6B](#F6){ref-type="fig"}, orange; Kruskal--Wallis test followed by Dunn's nonparametric test). We also observed that graded expression of CA-MLCK, which increases p-RLC (*x*-axis is from [Figure 3A](#F3){ref-type="fig"}), preferentially increased both the elastic energy dissipated by the fiber (*L~o~*) and the viscoelastic time constant (τ) of peripheral SFs (dark-gray circles) in a graded manner but did not alter the properties of central SFs ([Figure 6C](#F6){ref-type="fig"}, orange circles; Spearman correlation for *L~o~*: ρ~peripheral~ = 0.31, ρ~central~ = 0.018; Spearman correlation for τ: ρ~peripheral~ = 0.23, ρ~central~ = 0.028). The increase in *L~o~* and τ of peripheral SFs with increased p-RLC follows a nonlinear relationship with the properties not changing significantly until p-RLC reaches at least a 2.5-fold increase ([Figure 6C](#F6){ref-type="fig"}). Graded expression of CA-ROCK2, which led to an increase in the amount of pp-RLC (*x*-axis is from [Figure 3B](#F3){ref-type="fig"}), preferentially increased the elastic energy dissipated by the fiber after SLA (*L~o~*) and the viscoelastic time constant (τ) of central SFs ([Figure 6D](#F6){ref-type="fig"}, orange circles; Spearman correlation for *L~o~*: ρ~peripheral~ = 0.026, ρ~central~ = 0.56; Spearman correlation for τ: ρ~peripheral~ = 0.077, ρ~central~ = 0.29). *L~o~* appeared to increase linearly with pp-RLC, and at approximately a 3.5-fold increase in pp-RLC above basal levels, the viscoelastic character of central SFs matched that of peripheral SFs. The increase in τ followed a decaying nonlinear curve, eventually reaching a plateau at approximately a 3.5-fold increase in pp-RLC ([Figure 6D](#F6){ref-type="fig"}). These results suggest that SF mechanical properties are indeed tunable based on the type and amount of phosphorylated RLC present.

Our results indicate that ROCK and MLCK phosphorylate RLC in a preferential manner; MLCK primarily monophosphorylates RLC (Ser19), whereas ROCK 1 and ROCK 2 preferentially diphosphorylate it (Thr18 and Ser19; [Figure 3](#F3){ref-type="fig"} and Supplemental Figure S2). We also show that these changes in phosphorylation have specific localizations: MLCK-induced p-RLC localizes primarily in the periphery of the cell, whereas ROCK-induced pp-RLC localizes in the center ([Figure 4](#F4){ref-type="fig"}). Finally, we show that SF mechanical properties are also regulated preferentially via the kinases: ROCK controls central SF retraction kinetics, whereas MLCK controls peripheral retraction kinetics ([Figures 5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}). However, these results leave open the question of whether ROCK and MLCK-induced changes in RLC phosphorylation and SF properties are causally linked as opposed to unrelated epiphenomena. To provide a direct link between the kinases, MLC phosphorylation states, and SF mechanics, we transduced U2OS RFP-LifeAct cells with monophosphomimetic RLC, where Ser19 was mutated to Asp (RLC-AD), or with diphosphomimetic RLC, where both Thr18 and Ser19 were mutated to Asp (RLC-DD; [@B57]). We first noted that U2OS phosphomimetic-expressing cells phenocopy the SF architecture of U2OS CA-MLCK and CA-ROCK2 cells. Specifically, U2OS GFP RLC-AD cells show an elongated phenotype with bright peripheral SFs, whereas U2OS GFP RLC-DD cells exhibit bright central SFs ([Figure 7, A](#F7){ref-type="fig"} and B). We then wished to determine whether these phosphomimetic species localize in similar patterns as those observed earlier ([Figure 3](#F3){ref-type="fig"}). GFP-RLC AD localizes strongly on peripheral SFs ([Figure 7, A](#F7){ref-type="fig"} and B, white arrows), whereas GFP-RLC DD localizes primarily on central SFs (yellow arrows). We quantified the GFP signal of RLC-AD and RLC-DD on both peripheral and central SFs and calculated a localization ratio in which \>1 indicates preferential localization to peripheral SFs, whereas \<1 indicates preferential localization to central SFs. Analogous to the immunostaining studies ([Figure 3](#F3){ref-type="fig"}), we observed that GFP RLC-AD localizes preferentially to peripheral SFs, whereas GFP RLC-DD localizes to central SFs ([Figure 7C](#F7){ref-type="fig"}). Finally, we performed SLA on peripheral ([Figure 7D](#F7){ref-type="fig"}) and central SFs ([Figure 7E](#F7){ref-type="fig"}) of RLC-AD and RLC-DD cells. Overexpression of RLC-AD affected only the elastic energy (*L~o~*) dissipated by peripheral SFs (*p* = 0.029) and not central SFs (*p* = 0.63), phenocopying the results seen with CA-MLCK expression ([Figure 7D](#F7){ref-type="fig"}). In turn, overexpression of RLC-DD affected only the elastic energy (*L~o~*) dissipated by central SFs (*p* \< 0.0001) and not peripheral SFs (*p* = 0.72), phenocopying the results obtained via CA-ROCK2 expression ([Figure 7E](#F7){ref-type="fig"}). These results suggest that the changes in the viscoelastic retraction parameters observed from the increased expression of kinases are directly due to the changes in RLC phosphorylation.

![Expression of phosphosmimetic p-RLC and phosphomimetic pp-RLC phenocopy the changes in SF viscoelasticity induced by CA-MLCK and CA-ROCK. Representative images of (A) U2OS RFP-LifeAct GFP-RLC AD and (B) U2OS RFP-LifeAct GFP-RLC DD. Images are taken using the GFP channel for the phosphomimetic constructs and phalloidin for SFs. White arrows point to peripheral SFs, whereas yellow arrows point to central SFs. (C) Quantification of GFP signal localization as a ratio of localization on peripheral over central SFs (*n* = 36 for GFP-RLC AD and 30 for GFP-RLC DD). (D) *L~o~* and τ values of peripheral SF ablation for U2OS RFP-LifeAct, U2OS RFP-LifeAct GFP RLC-AD, and U2OS RFP-LifeAct GFP RLC-DD cells (*n* = 21, 28, and 28 cells, respectively). (E) *L~o~* and τ values of central SF ablation for U2OS RFP-LifeAct, U2OS RFP-LifeAct GFP RLC-AD, and U2OS RFP-LifeAct RFP RLC-DD cells (*n* = 22, 23, and 31 cells, respectively). Boxes represent 25th and 75th percentiles; whiskers represent 10th and 90th percentiles. Cross represents the distribution mean. Statistical differences calculated using Mann-Whitney tests (\*\< 0.05, \*\**p* \< 0.001, \*\*\**p* \< 0.0001). Scale bars = 10 µm.](3832fig7){#F7}

DISCUSSION
==========

ROCK and MLCK are broadly understood to govern RLC phosphorylation, thereby regulating the assembly and contraction of SFs. While there is much evidence that ROCK and MLCK respectively regulate the assembly and contractility of central and peripheral SFs ([@B52]; [@B22]; [@B51]), it has remained unclear how each kinase controls RLC phosphorylation states or how these states influence SF viscoelastic properties. By combining cell and molecular biological approaches with mechanical measurements of single SFs in living cells, we have provided support for a model in which MLCK and ROCK distinctly regulate peripheral and central SF mechanics via differential phosphorylation of RLC. Specifically, MLCK stimulates production of p-RLC, which localizes to and controls peripheral SF viscoelasticity. In contrast, both ROCK isoforms stimulate production of pp-RLC, which localizes to and controls central SF viscoelasticity ([Figure 8](#F8){ref-type="fig"}). The mechanical effects of each kinase can be recapitulated with overexpression of a corresponding mono- or diphosphomimetic RLC, strongly supporting a causal link between kinase activity, RLC phosphorylation states, and SF viscoelastic properties.

![Model of subcellular regulation of RLC phosphorylation and SF viscoelastic properties. MLCK-induced p-RLC localizes and regulates the viscoelastic properties of peripheral SFs, whereas ROCK1 and 2--induced pp-RLC localizes and regulates viscoelastic properties of central SFs.](3832fig8){#F8}

As noted earlier, previous efforts to dissect contributions of ROCK and MLCK to RLC phosphorylation have produced results that vary with the method used to study and perturb each kinase. In reconstituted preparations, MLCK has been observed to produce both p-RLC and pp-RLC; however, pp-RLC requires comparatively high MLCK concentrations (0.1--1 µM), leaving open the question of which phosphospecies is favored under more physiological conditions ([@B15]; [@B16]; [@B48]). While pharmacological inhibition in cell culture of either ROCK or MLCK has been observed to reduce diphosphorylation of RLC ([@B59]), the interpretation of these results is complicated by the fact that MLCK and ROCK inhibitors can produce SF and FA disassembly at sufficiently high dose, create off-target effects, and lack isoform selectivity. Moreover, studies of ROCK/MLCK effects on RLC phosphorylation have not been systematically coupled to measurements of contractile function. Our study begins to close this loop by combining controlled expression of each kinase with measurements of viscoelastic properties of individual SFs. We show that overexpression of CA-ROCK1 and CA-ROCK2 preferentially influences the viscoelastic parameters of central SFs ([Figures 5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"} and Supplemental Figure S3). Our results also reveal that overexpression of a short CA-MLCK that does not localize to SFs preferentially increases the stored elastic energy (as reflected by *L~o~*) and viscoelastic time constant (τ) of peripheral SFs. It should be informative to apply long MLCK mutants of varying actin-binding abilities and determine how the viscoelastic properties of peripheral SFs are altered by direct MLCK binding.

Although SF tension generation has been shown to depend on RLC phosphorylation, it has remained unclear whether graded changes in myosin activation produce graded changes in SF tension generation, or whether there are instead activation thresholds at which SF tension changes in a concerted manner ([@B19]). We find that graded increases in the expression of either CA-MLCK or CA-ROCK2 produce monotonic increases in both RLC phosphorylation and SF elastic energy. To our knowledge, this represents the first indication that SF viscoelastic properties can be tuned over a continuous range based on kinase activity. Furthermore, we were able to quantitatively map the relationship between whole-cell RLC phosphorylation levels and individual SF properties. Surprisingly, the viscoelastic properties of peripheral SFs depend much more nonlinearly on p-RLC levels than central SF mechanics depend on pp-RLC levels, indicating that central SFs may be more sensitive to small perturbations above basal RLC phosphorylation levels than peripheral SFs. Moreover, these correlations juxtapose properties of single SFs against whole-cell measurements of p-RLC and pp-RLC, which is a consequence of our inability to perform SLA in live cells while simultaneously performing antibody-based detection of phospho-RLC levels. It should be noted that our measured fold changes in RLC phosphorylation cannot be used to infer stochiometric ratios of p-RLC and pp-RLC within a given cell or SF. It would be valuable to revisit these MLCK and ROCK manipulations, measure the effects on p-RLC/pp-RLC ratios (e.g., with mass spectrometry or urea/glycerol gel electrophoresis), and ask if these ratios are predictive of SF viscoelastic properties. Additionally, fiber-by-fiber correlations of phospho-RLC states and viscoelastic properties may be facilitated in the future by geometric standardization of SFs ([@B20]) or through the use of live-cell kinase probes. Finally, further work is required to discern the relationship of each kinase to NMMIIA and IIB heavy isoform and their respective localization to central and peripheral SFs ([@B1], [@B2]; [@B6]).

Within the region of ROCK isoform activities probed, we did not observe strong differences between ROCK1 and ROCK2 in regulation of RLC phosphorylation, SF formation, or SF viscoelastic properties. Recent ROCK isoform-specific knockdown studies have revealed that ROCK1 preferentially regulates pp-RLC, whereas ROCK2 preferentially regulates p-RLC in CHO.K1 and REF52 cells, and that the two isoforms play differential roles in migration ([@B31]; [@B33]). Moreover, ROCK1 knockdown in MCF-7 cells specifically reduced p-RLC localization to adherens junctions suggesting that ROCK1 preferentially regulates contractility in adherens junctions ([@B35]). On the other hand, ROCK1 and ROCK2 have also been observed to serve redundant functions in other settings; ROCK1- and ROCK2-null fibroblasts showed similarly small reductions in RLC diphosphorylation and cell contractility relative to wild-type controls with statistically significant effects seen only when both ROCK isoforms were removed ([@B24]). Additional differences may arise from the method of ROCK isoform perturbation (i.e., overexpression vs. knockdown). These distinct regimes of kinase activity may produce divergent effects on RLC phosphorylation states due to the complex and potentially nonlinear relationships between these RLC activators, ROCK-inhibited RLC phosphatase and RLC phosphorylation ([@B58]; [@B19]). It is important to acknowledge that previous work has suggested that phosphomimetic RLCs (TE or EE) may not mimic endogenous phosphorylated RLC in in vitro assays and in *Drosophila*. We observed that phosphomimetic RLCs used in this study (AD and DD) emulated the localization patterns of p-RLC and pp-RLC, phenocopied the SF architecture changes triggered by MLCK-induced p-RLC and ROCK-induced pp-RLC, and congruently altered SF viscoelastic changes ([@B18]; [@B47]; [@B55]). Nonetheless, additional characterization of these and related RLC mutants would help assess the degree to which they capture the effects of phosphorylation.

Overall, our work highlights a potential mechanism for cells to spatially and temporally regulate the distribution of contractile forces via preferential phosphorylation from different kinases. The distinct contributions of each phosphospecies to SF viscoelasticity may involve multiple protein--protein interactions, given that highly reductionist myosin sliding assays do not detect differences in velocities between p-RLC and pp-RLC ([@B54]). Nevertheless, with the many recent efforts to develop multiscale mechanochemical models of SF function ([@B40]; [@B45]; [@B7]; [@B37]; [@B44]), data such as ours may offer valuable new inputs for these models and facilitate incorporation of distinct subcellular pools of SFs.

MATERIALS AND METHODS
=====================

Cell lines and reagents
-----------------------

Myc-tagged human p160ROCK Δ3 (kindly provided by S. Narumiya, Kyoto University, Japan), Flag-tagged rabbit smooth muscle MLCK ED785-786KK (kindly provided by P. J. Gallagher, Indiana University), and bovine ROCK CAT (kindly provided by K. Kaibuchi, Nagoya University, Japan) were subcloned into the lentiviral vector pSLIK (Addgene \#84647 for CA-MLCK and \#84649 for CA-ROCK2; [@B29]; [@B61]). This vector contains a tet response element (TRE) doxycycline-inducible promoter, along with constitutive expression of a reverse tetracycline-controlled transactivator (rtTA) and Venus selection marker separated by an internal ribosomal entry site (IRES) ([Figure 1A](#F1){ref-type="fig"}). p160ROCK Δ3 is a CA mutant of the ROCK1 isoform, whereas ROCK CAT is a CA mutant of the ROCK2 isoform. Our sequencing reveals that this CA-MLCK bears 98% identity to rabbit smooth muscle MLCK (∼150 kDa) but harbors a mutation within the autoinhibitory site (ED773-774KK of construct, which aligns with ED785-786KK in wild-type MLCK; GenBank accession number: MG189932). This mutation has previously been shown to confer CA function in bovine smooth muscle MLCK through disruption of autoinhibition ([@B10]). Empty pSLIK vectors were also used to establish control cell lines. Viral particles for each pSLIK plasmid and for the pFUG-RFP-LifeAct vector were packaged in 293T cells. U2OS osteosarcoma cells (ATCC HBT-96) were transfected with pFUG-RFP-LifeAct and sorted on a DakoCytomation MoFlo High Speed Sorter based on red fluorescent protein (RFP) fluorescence ([@B25]). U2OS RFP-LifeAct cells were further stably transduced with the pSLIK vectors at a multiplicity of infection (MOI) of 0.5 IU/cell. Cells were further sorted based on RFP and Venus fluorescence. U373MG glioblastoma cells (ATCC HTB-17, also known as U-373 MG) were transfected with the pSLIK plasmids at an MOI of 0.5 IU/cell, and cells receiving the construct were selected based on Venus fluorescence. U373MG cells containing the pSLIK plasmid were then transfected with pFUG-RFP-LifeAct at an MOI of 1.5 IU/cell and cells receiving the LifeAct vector were selected using 0.6 μg/ml puromycin. ATCC U373MG cells have been established to be derived from a common progenitor with U251 cells and SNB 19 cells, although the lines have diverged and exhibit some phenotypic and karyotypic differences ([@B46]). Both cell lines were confirmed by short tandem repeat profiling, and mycoplasma testing was carried out every 4 mo.

Plasmids containing phosphomimetic myosin light chains (pEGFP RLC-DD, pEGFP RLC-AD) were kindly provided by A. R. Horwitz (University of Virginia; [@B57]). The RLC-GFP constructs were digested from the plasmid backbone using *Eco*RI and *Xho*I and ligated into the lentiviral vector pLVX-AcGFP-N1 (Clonetech). Successful ligation was verified via sequencing. Viral particles for each plasmid were packaged in 293T cells. U2OS RFP-LifeAct cells were stably transduced with the viral particles at an MOI of 0.5 IU/cell. Cells were then sorted based on RFP and green fluorescent protein (GFP) fluorescence.

U2OS cells were cultured in DMEM supplemented with 10% fetal bovine serum (JR Scientific), 1% penicillin/streptomycin (Thermo Fisher Scientific), and 1% nonessential amino acids (Life Technologies). U373MG cells were cultured in DMEM supplemented with 10% calf serum (JR Scientific), 1% penicillin/streptomycin, 1% nonessential amino acids, and 1% sodium pyruvate (Thermo Fisher Scientific). Doxycycline (Fisher Bioreagents) was added at the required concentration 2 d before all experiments to activate the CA constructs.

Western blots
-------------

As described previously, cells were lysed in radioimmunoprecipitation assay (RIPA) buffer with phosphatase and protease inhibitors (EMD Millipore, Billerica, MA; [@B61]; [@B20]). Protein content was measured by bicinchoninic acid (BCA) assay and used to normalize samples to the lowest concentration. Lysates were boiled, run on 4--12% Bis-Tris gels, and transferred onto a polyvinylidene difluoride (PVDF) membrane. The following primary antibodies were used: anti-phosphorylated myosin light chain 2 (Thr18/Ser19; Cell Signaling Technology), anti-phosphorylated myosin light chain 2 (Ser19) produced in rabbit or in mouse (both obtained from Cell Signaling Technology), anti-GAPDH (Sigma-Aldrich, St. Louis, MO), mouse anti-MLCK (Sigma-Aldrich, St. Louis, MO) and rabbit anti-MLCK (abcam), anti-ROCK 2 (Sigma-Aldrich, St. Louis, MO), anti-Myc tag (Cell Signaling Technology), and anti-ROCK1 (Cell Signaling Technology). The following secondaries were used: IRDye 800 Goat anti-mouse IgG, IRDye 700 Goat anti-rabbit IgG (Licor), and HRP-conjugated anti-mouse (Life Technologies). All bands except Myc tag for CA-ROCK1 visualization (Supplemental Figure S1) were visualized using an Odyssey system and were quantified with the built-in gel analyzer tool in ImageJ (National Institutes of Health \[NIH\], Bethesda, MD). Myc-tag bands were visualized using enhanced chemiluminiscence (ECL; Thermo Fisher) reagent.

Immunofluorescence staining
---------------------------

Cells were seeded on glass coverslips coated with 25 μg/ml fibronectin (EMD Millipore Corporation). After doxycycline incubation, cells were fixed with 4% paraformaldehyde for 10 min at room temperature. After phosphate-buffered saline (PBS) washes, cells were permeabilized in 0.5% Triton-X for 15 min, and blocked in 5% goat serum (GS; Thermo Fisher Scientific) for at least 1 h. U2OS cells were incubated in 1% GS and primary antibody for 2 h at room temperature or overnight at 4°C in a humidity chamber. U373MG cells were incubated in 1% GS and primary antibody overnight at 4°C. Following primary incubation, cells were washed in 1% GS (3 × 5 min) and then incubated in secondary antibody for 1 h at room temperature. We used the following antibodies: anti-phosphorylated myosin light chain 2 (Thre18/Ser19) produced in rabbit (Cell Signaling Technology), anti-phosphorylated myosin light chain 2 (Ser19) produced in mouse (Cell Signaling Technology), anti-MLCK (Sigma-Aldrich, St. Louis, MO), anti-ROCK2 (Sigma-Aldrich, St. Louis, MO), anti-ROCK1 (Cell Signaling Technologies), Alexa Fluor 647 anti-mouse, Alexa Fluor 488 anti-rabbit, and Alexa Fluor 633 anti-rabbit (Thermo Fisher Scientific). F-Actin was stained with 546-phalloidin. U373MG cells were mounted on glass slides using ProLong Gold Antifade Mountant (Thermo Fisher Scientific). [Figure 4](#F4){ref-type="fig"} immunofluorescence images were obtained using a swept-field upright confocal microscope equipped with a 60× water-immersion lens (Prairie Technologies) and a Nikon TE2000 microscope equipped with a 60× oil immersion lens. Supplemental Figure S4 images were obtained on a Zeiss LSM 510 Meta Confocal microscope equipped with a 63× oil immersion objective and a Nikon TE2000 microscope equipped with a 60× oil immersion lens. For presentation purposes, the contrast and brightness of fluorescence images were optimized using ImageJ (NIH).

Analysis of immunofluorescence images
-------------------------------------

All analyses were performed using ImageJ. To quantify the localization of p-RLC and pp-RLC, images were overlaid with phalloidin and background was subtracted. Alignment of images was verified using Template Matching plug-in ([@B53]). A line of 0.6 µm thickness was manually drawn over peripheral or central SFs for multiple SFs per cell and a measurement of raw integrated intensity of p-RLC and pp-RLC was recorded across each traced line. The intensities were then normalized to the length of the drawn line and averages of normalized intensities were calculated per cell. To account for experiment-to-experiment variations in fluorescence intensity, values were normalized to the mean value of the appropriate control, that is, CA-ROCK2 or CA-MLCK cells cultured in 0 ng/ml doxycycline for each specific experiment.

To quantify the localization of GFP RLC-AD and GFP RLC-DD, cells were seeded on 25 µg/ml fibronectin-coated coverslips and fixed using 4% paraformaldehyde. Cells were permeabilized and incubated with Alexa 546-tagged phalloidin. Images of SFs and phosphomimetic species were obtained using a 63× oil immersion objective. A line of 0.6 µm was drawn over peripheral and central SFs and the intensity of the GFP signal was recorded. The intensities were then normalized to the length of the drawn line and averages of normalized intensities were calculated per cell. The ratio of peripheral to central SF localization was then determined.

SF photodisruption
------------------

SF SLA experiments were performed on a Zeiss LSM 510 Meta Confocal microscope equipped with a MaiTai Ti:sapphire femtosecond laser (Spectra Physics, Newport Beach, CA; [@B51]; [@B6]). Cells (10,000) were seeded on 35-mm glass bottom dishes (MatTek Corporation) coated with 25μg/ml fibronectin (EMD Millipore Corporation) and incubated in doxycycline for 2 d. Media was changed to Live Cell Imaging Solution (Invitrogen) before SLA. For SF photodisruption, the femtosecond laser was used at 770 nm resulting in an energy deposition of 1--2 nJ on a single SF ([@B51]; [@B6]; [@B20]). All images were acquired with a 40× water-immersion objective (N.A. = 0.8).

Data analysis of SF retraction
------------------------------

SF retraction distance was recorded every 2 s for 49 s following SLA. The SF ends were manually traced using Image J to determine the retraction dynamics. Results were fitted to a Kelvin-Voigt model defined by the following equation: where *L* is defined as half the distance between the two severed SF ends, *D~a~* is the length of SF destroyed by the laser, *L~o~* is the retraction plateau distance, and τ is the viscoelastic time constant. Curve fitting to extract parameters *L~o~* and τ was performed using CurveFit (MATLAB; [@B51]; [@B6]; [@B20]).

Statistical analysis
--------------------

All statistical analyses and graph generation were performed using GraphPad Prism and *R*. Unless otherwise noted, samples were compared using nonparametric *t* tests such as Mann-Whitney. Normality was assessed based on the Shapiro-Wilk Normality test. Experiments that used cells seeded and assayed on different days were deemed independent, and at least three independent experiments were performed for each assay.
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MLCK

:   myosin light chain kinase

NMMII

:   nonmuscle myosin II

p-RLC

:   monophosphorylated myosin regulatory light chain

pp-RLC

:   diphosphorylated regulatory light chain

RLC

:   myosin regulatory chain

ROCK

:   Rho-associated kinase

SF

:   stress fiber

SLA

:   subcellular laser ablation.
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